S119: PRELIMINARY RESULTS OF A PHASE 1 STUDY IN HEALTHY SUBJECTS ADMINISTERED INCLACUMAB, A FULLY HUMAN IGG4 ANTI-P-SELECTIN MONOCLONAL ANTIBODY IN DEVELOPMENT FOR TREATMENT OF SICKLE CELL DISEASE. (31st January 2022) - Mayer, C; Cooper, D; Redfern, A; Geng, X; Shi, J; Zutphen-van Geffen, M; Kuan, I; Koek, K; Kastrissios, H; Patel, K; Davis, M; Yue, P